不良核型急性髓系白血病首次完全缓解期单倍体、10/10与9/10无关供者移植结局相当
该研究基于EBMT登记库2007至2015年数据,比较了不良细胞遗传学急性髓系白血病首次完全缓解期接受T细胞去除单倍体(n=74)、10/10无关供者(n=433)与9/10无关供者(n=123)移植患者的结局。2年非复发死亡率、复发率、无白血病生存率与总生存率在各供者类型间均无显著差异,急性与慢性移植物抗宿主病发生率亦与供者类型无关。多变量Cox模型显示单倍体移植与10/10及9/10无关供者移植的总生存率与无白血病生存率相当。
要点
- 2年非复发死亡率单倍体19%、10/10无关供者18%、9/10无关供者18%(P=.9)。
- 2年复发率单倍体27%、10/10无关供者39%、9/10无关供者37%(P=.3)。
- 2年无白血病生存率与总生存率各组间无显著差异(P均=.5)。
核心结论
- 在不良细胞遗传学急性髓系白血病首次完全缓解患者中,单倍体移植受者的结局与10/10及9/10无关供者移植相当,提示这些移植类型均可视为该高危人群的有效选择。
研究设计与样本
- 回顾性分析EBMT登记库2007至2015年报告的接受T细胞去除单倍体(n=74)、10/10无关供者(n=433)和9/10无关供者(n=123)造血干细胞移植的患者。
- 不良风险急性髓系白血病按2017 ELN细胞遗传学风险分类定义。
主要发现
- 2年非复发死亡率单倍体19%、10/10无关供者18%、9/10无关供者18%(P=.9)。
- 2年复发率单倍体27%、10/10无关供者39%、9/10无关供者37%(P=.3),供者来源未显著影响复发。
- 2年无白血病生存率单倍体53%、10/10无关供者43%、9/10无关供者44%(P=.5)。
- 2年总生存率单倍体59%、10/10无关供者50%、9/10无关供者50%(P=.5)。
- 供者类型与急性和慢性移植物抗宿主病发生率均无显著关联;多变量Cox模型显示单倍体移植受者的总生存率与无白血病生存率与10/10及9/10无关供者相当。
临床怎么用
- 作者认为,在不良细胞遗传学急性髓系白血病首次完全缓解患者中,单倍体、10/10无关供者及9/10无关供者移植均可考虑为有效选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most powerful therapy preventing relapse in patients with adverse cytogenetics acute myeloid leukemia (AML) in first complete remission (CR1). In the absence of a matched related donor, potential alternatives include 10/10, 9/10 HLA-matched unrelated (UD) or haploidentical (Haplo) donors. We analyzed clinical outcomes of patients undergoing T-cell repleted Haplo (n = 74), 10/10 UD (n = 433) and 9/10 UD HSCT (n = 123) from 2007 to 2015, reported to the EBMT Registry. Adverse risk AML was defined according to the 2017 ELN cytogenetic risk classification. The 2-year nonrelapse mortality was 19% for Haplo, 18% for 10/10 UD and 18% for 9/10 UD (P = .9). The relapse incidence was not significantly affected by donor source, with a 2-year incidence of 27% for Haplo HSCT, 39% for 10/10 UD and 37% for 9/10 UD SCT (P = .3). We show comparable probabilities of leukemia-free survival (LFS) and overall survival (OS) at 2 years among Haplo HSCT, 10/10 UD SCT and 9/10 UD SCT (53% and 59%, 43% and 50%, 44% and 50%, respectively, P = .5 for both parameters). The type of donor was not significantly associated with either acute or chronic graft-vs.-host disease incidence. Using multivariable Cox model, Haplo HSCT recipients experienced comparable OS and LFS to 10/10 and 9/10 UD. In the present series of adverse cytogenetics AML patients in CR1, Haplo HSCT recipients had comparable outcomes to those of 10/10 and 9/10 UDs, suggesting that all these types of HSCT may be considered a valid option in this high risk population.
引用
- Lorentino F, Labopin M, Bernardi M, et al. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018. PMID: 30058714. doi:10.1002/ajh.25231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。